DA
Doliver Advisors’s Thermo Fisher Scientific TMO Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.52M | Buy |
3,742
+835
| +29% | +$339K | 0.42% | 39 |
|
|
2025
Q1 | $1.45M | Buy |
2,907
+104
| +4% | +$51.8K | 0.41% | 40 |
|
|
2024
Q4 | $1.46M | Buy |
2,803
+44
| +2% | +$22.9K | 0.41% | 41 |
|
|
2024
Q3 | $1.71M | Sell |
2,759
-78
| -3% | -$48.3K | 0.47% | 35 |
|
|
2024
Q2 | $1.57M | Buy |
2,837
+21
| +0.7% | +$11.6K | 0.44% | 37 |
|
|
2024
Q1 | $1.64M | Sell |
2,816
-18
| -0.6% | -$10.5K | 0.46% | 35 |
|
|
2023
Q4 | $1.5M | Buy |
2,834
+35
| +1% | +$18.6K | 0.46% | 39 |
|
|
2023
Q3 | $1.42M | Sell |
2,799
-33
| -1% | -$16.7K | 0.43% | 35 |
|
|
2023
Q2 | $1.48M | Buy |
2,832
+140
| +5% | +$73K | 0.45% | 32 |
|
|
2023
Q1 | $1.55M | Buy |
2,692
+120
| +5% | +$69.2K | 0.49% | 30 |
|
|
2022
Q4 | $1.42M | Buy |
2,572
+44
| +2% | +$24.2K | 0.47% | 33 |
|
|
2022
Q3 | $1.28M | Buy |
2,528
+168
| +7% | +$85.2K | 0.47% | 30 |
|
|
2022
Q2 | $1.28M | Buy |
2,360
+461
| +24% | +$250K | 0.46% | 38 |
|
|
2022
Q1 | $1.12M | Buy |
1,899
+163
| +9% | +$96.3K | 0.35% | 52 |
|
|
2021
Q4 | $1.03M | Sell |
1,736
-629
| -27% | -$374K | 0.32% | 52 |
|
|
2021
Q3 | $1.35M | Buy |
2,365
+203
| +9% | +$116K | 0.45% | 41 |
|
|
2021
Q2 | $1.09M | Buy |
2,162
+542
| +33% | +$274K | 0.36% | 47 |
|
|
2021
Q1 | $739K | Buy |
1,620
+805
| +99% | +$367K | 0.27% | 63 |
|
|
2020
Q4 | $380K | Buy |
+815
| New | +$380K | 0.17% | 89 |
|